Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Wegovy org - The Untold Story

Wegovy Tragedy: Woman in Pain with 'Black Tongue' and Lost Organ After Weight Loss Jabs

Sarah-Jayne Crawford's weight-loss journey with Wegovy turned tragic, leading to severe health issues and organ removal. She now warns others about the potential risks of such treatments.

International Business Times UK

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

Barchart

‘Major turning point’ as weight loss drugs to be prescribed to more NHS patients

Wegovy can now be prescribed for weight loss or to help reduce the risk of major cardiovascular events

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Ozempic Controversy Deepens as FDA Accuses Novo Nordisk of Failing to Report Patient Deaths, One Linked To Suicide

Novo Nordisk faces FDA scrutiny for failing to report Ozempic-linked deaths, highlighting systemic issues in safety reporting. Learn about the implications for patient safety and ongoing legal challenges.

International Business Times UK

Weight-loss jab could be made for $3 a month, study finds

Cheap semaglutide, the drug in Ozempic and Wegovy, could help millions with diabetes and obesity in 160 countries

The Guardian - UK

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is labelled ‘obsolete’

Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations

The Guardian - UK

Why Denmark can't use Ozempic as a trump card with the US in Greenland talks

Novo Nordisk, the Danish manufacturer of weight-loss drugs Ozempic and Wegovy, has a large market share in the US. But it's not enough to put pressure on US President Donald Trump's administration during Greenland talks, experts say.

Euronews

Read news from The Economist, FT, and more,
with one subscription

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

MarketBeat

Weight-loss wonder drugs 'no substitute for exercise'

The weight-loss journey for a growing number of Australians using "miracle" medications must include exercise or risk long-term health problems, experts warn.

AAP

Novo Nordisk Q3 2025 Earnings Call Transcript

Novo Nordisk A/S (NASDAQ:NVO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. NVO is having a challenging session. See if it is worth your attention here. This transcript is brought to you by Benzinga APIs. For real-time access to our entire…

Benzinga

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

Benzinga

Novo Nordisk Freezes Hiring As Wegovy Faces Copycats

Novo Nordisk A/S (NYSE:NVO) has reportedly imposed a global hiring freeze for nonessential roles, as the drugmaker faces rising competition from copycat versions of Wegovy and intensifying rivalry with Eli Lilly and Co (NYSE:LLY).

Benzinga

GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access

GoodRx Holdings Inc. (NASDAQ:GDRX) shares jumped 5.08% in after-hours trading on Monday, following the announcement of a collaboration with Novo Nordisk A/S (NYSE:NVO) to offer discounted GLP-1 medications at fixed pricing nationwide.

Benzinga

Novo Nordisk Surges On Wegovy Win, Eyes Bullish Rebound Near 52-Week Lows

Novo Nordisk A/S (NYSE:NVO) may have found a timely catalyst. From the lows of its 52-week trading range, the Danish drugmaker is showing signs that a bullish comeback might be on the horizon—driven by both regulatory approval momentum and technically solid market signals.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3…

The Independent UK

‘I lost four stone on Mounjaro – but piled weight back on when I couldn’t afford to keep taking it’

Darren Ratcliffe was paying £270 a month for weight-loss jab Mounjaro

Benzinga

Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

Benzinga

Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday.

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Benzinga

Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert

The Independent UK

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging

Benzinga

Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'

Hims Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant.

Barchart

Novo Nordisk Just Axed Its Deal with Hims & Hers. Should You Buy the Dip in HIMS Stock?

Hims & Hers stock tumbles as Novo Nordisk terminates Wegovy deal. BofA warns of significant further downside in the HIMS share price.

The Independent UK

Weight-loss jab Mounjaro helps people shed much more weight than rival – study

Mounjaro (tirzepatide) and Wegovy (semaglutide) are weight-loss medicines that make people feel fuller for longer and therefore less hungry.

MarketBeat

Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.